PET Stress Tests Do Not Contain Iodine
No, PET stress tests do not contain iodine. PET cardiac stress tests use radiopharmaceuticals with very short half-lives such as rubidium-82 (Rb-82), nitrogen-13 (N-13) ammonia, or oxygen-15 (O-15) water, none of which contain iodine 1.
PET Stress Test Radiopharmaceuticals
PET myocardial perfusion imaging uses specific tracers that do not contain iodine:
These radiopharmaceuticals have extremely short half-lives, measured in minutes, which allows for lower radiation exposure compared to other imaging techniques 1
The average effective radiation dose for rest/stress PET with Rb-82 is approximately 3 mSv, which is significantly lower than other nuclear imaging techniques 1
Contrast Between PET and Other Imaging Modalities
Unlike some CT imaging procedures that may use iodinated contrast agents, PET cardiac stress tests rely on radioactive tracers that emit positrons 1
The PET imaging process detects the 511 keV energy photons produced when positrons interact with electrons in the body 1
When PET is combined with CT (PET/CT), the CT portion might use iodinated contrast in some cases, but this is separate from the PET radiopharmaceutical 2
Clinical Considerations
For patients with iodine allergies, a PET stress test is a suitable alternative to other imaging modalities that might require iodinated contrast 1
For pregnant or breastfeeding women, imaging using ionizing radiation should generally be avoided, but when necessary, PET has a lower radiation dose than some alternatives 1
PET stress testing is particularly valuable for:
Important Note on Iodine-124 in PET
While iodine-124 (I-124) is a positron emitter that can be used in some PET imaging applications (particularly for thyroid cancer), it is NOT used in cardiac PET stress tests 3, 4, 5
I-124 has a much longer half-life (4.2 days) compared to the radiopharmaceuticals used in cardiac PET stress tests, which have half-lives measured in minutes 3, 4
Cardiac PET stress tests specifically use Rb-82, N-13 ammonia, or O-15 water as the radiopharmaceuticals of choice 1